Edgeline Holdings, Inc. (OTCBB:ELHI), which recently announced a name change to Oncolin Therapeutics, Inc., announced today that one of its research programs for which it has rights was awarded a peer reviewed National Institute Of Health Grant for $179,000 to support research on thermally targeted delivery of Doxorubicin.
There is a great need to develop drugs that target tumors to provide increased efficacy and reduced toxicity. Preliminary results reported in this grant demonstrated that specific polypeptide doxorubicin conjugates showed increased cytoxicity and decreased toxicity when used in conjunction with hyperthermia. This research will be expanded to other drugs and animal testing to choose the best candidate to bring into clinical development.
Specific targeting of the proposed chemotherapeutic polypeptide carriers to solid tumors by local hyperthermia would increase specificity and efficacy of treatment and reduce the toxicity to normal tissues. This technology therefore represents a potential platform useful for a variety of chemotherapeutic agents.
“We are very happy that this program has received funding from such a prestigious organization as the NIH to help progress this potential platform technology,” commented Dr. Donald Picker, COO of Edgeline Holdings, Inc.
Recent News
Edgeline has recently announced it has obtained an exclusive option agreement with The University of Texas M.D. Anderson Cancer Center which provides the company the right to negotiate a license for five technologies relating to the treatment of various cancers over a nine month period.
In addition, Edgeline has recently announced a Joint Development Agreement with Houston Pharmaceuticals to assist the company in obtaining a license for certain patents, several of which are from the University of Mississippi and the University of Louisiana. Houston Pharmaceuticals will continue collaborations with both universities and assist them in securing grants on behalf of the company.
About Edgeline Holdings, Inc.
Headquartered in Houston, Texas, Edgeline Holdings, Inc. is a publicly traded biopharmaceutical company that engages in the discovery, development and commercialization of novel selective anticancer therapies.
Safe Harbor Statement
This press release contains statements that may constitute forward-looking statements, including the company's ability to successfully acquire and develop technologies that are and may be acquired. These statements are based on current expectations and assumptions and involve a number of uncertainties and risks that could cause actual results to differ materially from those currently expected. For additional information about Edgeline's future business and financial results, refer to Edgeline's Quarterly Report on Form 10-QSB for the quarter ended September 30, 2007, and Annual Report on Form 10-KSB for the year ended March 31, 2007. Edgeline Holdings undertakes no obligation to update any forward-looking statement that may be made from time to time by or on behalf of the company, whether as a result of new information, future events or otherwise.
Contacts:
J. Leonard Ivins, 713-621-5208
Investors@edgelineholdings.com
